Aurinia Q2 2026 revenue up 19% to $83.2M; net income $37.4M, EPS $0.28

Aurinia Pharmaceuticals Inc.

Total revenue $83.2M (+19% YoY); LUPKYNIS net product sales $79.4M (+19% YoY).
Net income $37.4M (+74% YoY); diluted EPS $0.28 (+75% YoY).
Cash from operations $52.5M; cash position $443.1M at June 30, 2026.
Reiterated 2026 total revenue guidance $315M-$325M (11-15% growth).
Initiated PRESERVE Phase 4 study combining LUPKYNIS with biologics; aritinercept in four indications.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.